UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.64 Million Position in Certara, Inc. (NASDAQ:CERT)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its stake in shares of Certara, Inc. (NASDAQ:CERT) by 12.2% during the 3rd quarter, Holdings Channel reports. The fund owned 225,704 shares of the company’s stock after selling 31,402 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Certara were worth $2,643,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. SG Americas Securities LLC bought a new position in shares of Certara during the 2nd quarter worth about $226,000. Blue Trust Inc. acquired a new position in Certara during the 2nd quarter worth approximately $26,000. Louisiana State Employees Retirement System boosted its holdings in Certara by 2.3% in the second quarter. Louisiana State Employees Retirement System now owns 54,200 shares of the company’s stock worth $751,000 after acquiring an additional 1,200 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Certara by 36.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 27,012 shares of the company’s stock worth $374,000 after acquiring an additional 7,158 shares in the last quarter. Finally, Innealta Capital LLC acquired a new stake in Certara in the second quarter valued at approximately $36,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the sale, the insider now directly owns 50,091 shares in the company, valued at approximately $552,503.73. This trade represents a 9.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.39% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently weighed in on CERT. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a research report on Friday, September 27th. Robert W. Baird decreased their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. Finally, Barclays dropped their price objective on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 7th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $15.92.

Certara Stock Down 2.0 %

Shares of NASDAQ:CERT opened at $11.47 on Friday. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of -57.35, a PEG ratio of 5.86 and a beta of 1.53. The business’s 50 day moving average is $10.84 and its 200 day moving average is $12.63. Certara, Inc. has a 12-month low of $9.41 and a 12-month high of $19.87. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. The firm had revenue of $94.80 million for the quarter, compared to the consensus estimate of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.06 EPS. On average, sell-side analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.